Amgen’s T-VEC Gets FDA Panel Endorsement – But On Wrong Question?
This article was originally published in The Pink Sheet Daily
Executive Summary
Joint advisory committee votes 22-1 to approve T-VEC for metastatic melanoma but several members favor restricting use to patients in earlier stages of disease; FDA not asking the ‘right question’ for approval, NCI representative says.